Annual report pursuant to Section 13 and 15(d)

Organization and Basis of Presentation (Details Narrative)

v3.7.0.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 03, 2015
Nov. 25, 2014
Jan. 02, 2014
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Common stock, shares authorized 800,000,000     800,000,000       800,000,000       800,000,000 800,000,000    
Losses from operations       $ 94,386 $ 1,894 $ 4,204 $ 5,334 $ 44,373 $ 3,590 $ 3,817 $ 2,168 $ 105,819 $ 53,948 $ 5,799  
Cash and cash equivalents       $ 3,640       $ 9,276       $ 3,640 $ 9,276 $ 3,970 $ 1,034
Biozone, Biozone Acquisitions Co., Inc [Member]                              
Equity ownership interest rate     60.00%                        
Biozone, Biozone Acquisitions Co., Inc [Member] | Series B Convertible Preferred Stock [Member]                              
Number of converted shares of common stock 205,083,086   1,000,000                        
Common stock, shares authorized 800,000,000                            
Cocrystal Discovery [Member] | Series B Convertible Preferred Stock [Member]                              
Common stock exchange ratio     7.454%                        
Number of common stock shares issued     1                        
Cocrystal, Cocrystal Holdings, Inc [Member] | Series A Preferred Stock [Member]                              
Number of common stock value issued   $ 184,800                          
Number of common stock shares issued   1,000,000                          
Number of options to purchase of common stock   $ 178,200                          
Number of options to purchase of common stock, shares   16,542,538                          
RFS Pharma, LLC [Member]                              
Number of options to purchase of common stock, shares   16,542,538                          
RFS Pharma, LLC [Member] | Series A Preferred Stock [Member]                              
Number of converted shares of common stock   340,760,802                          
Common stock, shares authorized   800,000,000                          
Number of options to purchase of common stock   $ 6,600                          
Number of options to purchase of common stock, shares   1,000,000